Correlation Between Sarepta Therapeutics and Editas Medicine

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Sarepta Therapeutics and Editas Medicine at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sarepta Therapeutics and Editas Medicine into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sarepta Therapeutics and Editas Medicine, you can compare the effects of market volatilities on Sarepta Therapeutics and Editas Medicine and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sarepta Therapeutics with a short position of Editas Medicine. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sarepta Therapeutics and Editas Medicine.

Diversification Opportunities for Sarepta Therapeutics and Editas Medicine

0.45
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Sarepta and Editas is 0.45. Overlapping area represents the amount of risk that can be diversified away by holding Sarepta Therapeutics and Editas Medicine in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Editas Medicine and Sarepta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sarepta Therapeutics are associated (or correlated) with Editas Medicine. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Editas Medicine has no effect on the direction of Sarepta Therapeutics i.e., Sarepta Therapeutics and Editas Medicine go up and down completely randomly.

Pair Corralation between Sarepta Therapeutics and Editas Medicine

Given the investment horizon of 90 days Sarepta Therapeutics is expected to generate 0.65 times more return on investment than Editas Medicine. However, Sarepta Therapeutics is 1.54 times less risky than Editas Medicine. It trades about 0.01 of its potential returns per unit of risk. Editas Medicine is currently generating about -0.15 per unit of risk. If you would invest  13,510  in Sarepta Therapeutics on September 1, 2024 and sell it today you would lose (176.00) from holding Sarepta Therapeutics or give up 1.3% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Sarepta Therapeutics  vs.  Editas Medicine

 Performance 
       Timeline  
Sarepta Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Sarepta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Sarepta Therapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.
Editas Medicine 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Editas Medicine has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Sarepta Therapeutics and Editas Medicine Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Sarepta Therapeutics and Editas Medicine

The main advantage of trading using opposite Sarepta Therapeutics and Editas Medicine positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sarepta Therapeutics position performs unexpectedly, Editas Medicine can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will offset losses from the drop in Editas Medicine's long position.
The idea behind Sarepta Therapeutics and Editas Medicine pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Complementary Tools

CEOs Directory
Screen CEOs from public companies around the world
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bonds Directory
Find actively traded corporate debentures issued by US companies